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Abstract: The primary objective in the study is determination of
efficacy of probiotic preparation as a supportive therapy in eradication
of Helicobacter pylori.
The study was multicenter, prospective, randomized, placebo con-
trolled, and double-blind. The subjects first filled out a specially
designed questionnaire to assess the severity of the 10 symptoms, which
can be related to eradication therapy to be monitored during the trial.
Each subject then received 28 capsules of probiotic preparation or
matching placebo capsules, which they were supposed to take over the
following 14 days, twice a day, at least 2 hours prior to or after the
antibiotic therapy administration.
A total of 804 patients were enrolled in the trial, of which 650
(80.85%) were included in the analysis. The results show a significantly
larger share of cured subjects in the probiotic arm versus the placebo
arm (87.38% vs 72.55%; P< 0.001). Additionally, presence and inten-
sity of epigastric pain, bloating, flatulence, taste disturbance, loss of
appetite, nausea, vomiting, heartburn, rash, and diarrhea weremonitored
over the study period. At 15 days postinclusion, probiotic treatment was
found superior to placebo in 7 of 10 mentioned symptoms. Average
intensity for symptoms potentially related to antibiotic therapy was
significantly higher in the placebo group, 0.76 vs 0.55 (P< 0.001).
Adding probiotics to the standard triple therapy for H pylori
eradication significantly contributes to treatment efficacy and distinctly
decreases the adverse effects of therapy and the symptoms of the
underlying disease.
(Medicine 94(17):e685)
Abbreviations: ARR = absolute risk reduction, BB-12 =
Bifidobacterium, CONSORT = Consolidated Standards of
Reporting Trials, H pylori = Helicobater Pylori, LGG =
Lactobacillus rhamnosus GG, NNT = number needed to treat,
OR = odds ratio, RRR = relative risk reduction.ic, MD, PhD, Kari ,
Davor Stimac, MD, PhD
articles of Russian scientist Ilya Ilyich Mechnikov,1 who noticed
that certain strains of Lactobacillus have the ability to eliminate
pathogenic bacteria from the gastrointestinal system.
Even at a glance, the literature reveals a significant number
of clinical studies on the use of probiotics,2 especially in the gas-
trointestinal indications such as antibiotic-induced diarrhea,3–8
other types of diarrhea like the so-called ‘‘traveller’s
diarrhea,’’9–12 andgastroenteritis in children13–17 andadults.18,19
In line with these findings, gastroenterologists and general
practitioners have increasingly more possibilities of prescribing
probiotic preparations as the only or (more often) adjuvant
therapy in certain indications. A significant step forward was
made in the current report of the European Helicobacter Study
Group,20 which considers probiotics as an adjuvant treatment in
reducing side-effects during the standard Helicobacter pylori
(H. pylori) eradication therapy. At this stage, probiotics are
classified as Grade D recommendation and that is the reason
why clinical studies are necessary for such effects to be
objectively proven in a clinical setting.
The role of probiotics in such treatment is to reduce the
number and intensity of side-effects and to act as an adjuvant to
standard treatment, resulting in better patient compliance and
better treatment outcome.
We aimed to conduct a clinical study for H pylori eradica-
tion using probiotics as an adjunctive treatment to standard
triple therapy regimen. The primary outcome of the study was
efficacy of eradication therapy and the secondary outcomes
were possible improvement of side-effects and tolerability of
eradication therapy by adding the probiotic preparation.
MATERIALS/METHODS
Study Population and Design
The trial was prospective, randomized, placebo-controlled,
double-blind, multicenter trial. It was conducted according to
the Declaration of Helsinki Principles and was approved by the
institutional review board. This study was performed in com-
pliance with Good Clinical Practices, including the archiving of
essential documents. The study was reported according to the
CONSORT guidelines and was registered at www.clinical
trials.gov (NCT01969331). Informed consent for this study
was obtained from all patients. Inclusion criteria were: con-
firmed H pylori infection, otherwise healthy subjects taking H
pylori eradication therapy, age above 18 years irrespective of
sex, and subjects who provided written informed consent prior
to undergoing any study procedure. Exclusion criteria were:
pregnancy or lactation; severe diseases such as malignant
diseases, decompensated renal, cardiac, pulmonary or livers not mentally capable of adhering to
iction or alcoholism; any other clinical
e opinion of the attending physician,
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would not allow safe administration of the study medications;
and subjects participating in any other clinical trial.
Probiotic preparation contains Lactobacillus rhamnosus
GG (LGG1) and Bifidobacterium (BB-121) in the concen-
tration of 108 to 1010 living bacteria capable of reproduction per
capsule (Normia1, JGL, Croatia, Christian Hanssen, Denmark).
The enrolment of subjects into the trial was conducted in
121 general practitioners’ offices, in different regions in Croatia
from December 2008 until December 2010.
The initial diagnosis of H pylori infection was established
using 1 of 3 commonly accepted methods—rapid urease test,
stool antigen, or urea breath test.21 After obtaining the informed
consent form, the subjects were enrolled in the trial and random-
ized either to the placebo arm or to the probiotic arm. All patients
received standard triple H pylori eradication therapy.
Randomization was centrally conducted using standard
methodologywith a computer-generated list.22 After assignment,
the participants and care providers (general practitioners) were
blinded to interventions. The subjects first filled out a specially
Hauser et aldesigned questionnaire to assess the severity of each of the 10
symptoms, which can be related to eradication therapy to be
monitored during the trial. Each subject then received 28 capsules
FIGURE 1. Comparison of treatment arms at 15 days, according to m
2 | www.md-journal.comof probiotic preparation or matching placebo capsules, which
they were supposed to take over the following 14 days, twice a
day, at least 2 hours prior to or after the antibiotic therapy
administration. Considered as nonadherent were subjects who
took <80% of either standard therapy or probiotic. Compliance
was monitored by counting the remaining medication at the
next study visit. The most common combinations of the
eradication therapy were omeprazole (2 20mg) or pantopra-
zole (2 40mg)þ clarithromycin (2 500mg)þ amoxicillin
(2 1000mg), followed by same combination but with metro-
nidazole (2 400mg) instead of amoxicillin. A number of other
treatments including lansoprazole as proton pump inhibitor (PPI)
(2 30mg) and azithromycin as antibiotic as well as other
combinations were responsible for the remaining 9% of study
treatments. Each study center was responsible for deciding what
combination to use.
In addition to the described initial visit, the subjects were
monitored during 2 additional visits—at 15 and 42 days after
enrolment. On the second visit, 15 days after the start of the trial,
Medicine  Volume 94, Number 17, May 2015the subjects again assessed the intensity of the 10 monitored
symptoms, as at enrolment, and their compliance was also
checked (Figure 1). On the third visit, 42 days after enrolment,
onitored symptoms.
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the diagnostic procedure to establish the presence of H pylori
was again conducted for each subject using the same method
that was used when the initial diagnosis was established except
for rapid urease test wherein we used one of the noninvasive
tests.
Outcome Measures
The primary endpoint of the trial was defined as the share
of subjects with successfully administered treatment, that is,
negative result for H pylori at 6 weeks (42 days 2 days). The
primary analysis of interest was the odds ratio (OR) for cure in
the probiotic treatment arm, versus the placebo treatment arm.
An additional objective was to monitor the intensity of each of
the 10 symptoms using a verbal rating scale consisting of 4
categories (from 0 [no symptoms] to 3 [severe symptoms]) at
baseline and at 2 weeks after enrolment.
Sample Size Calculation and Statistical Analysis
The sample size was calculated using the software package
NCSS/PASS23 to achieve appropriate statistical power
(b¼ 0.90), with the acceptable type 1 error (a¼ 0.05), and
hypothesis that the OR for cure in the probiotic treatment arm
versus placebo is at least 2. The required sample with the
aforementioned assumptions was 288 subjects per treatment
arm. With expected significant withdrawal of subjects during
the trial, the final number of enrolled subjects was slightly over
800 (Figure 2). The statistical analysis was conducted using the
Statistica24 software package, with the statistical significance
level set to 0.05. The values of categorical variables were shown
in contingency tables and compared using the x2 test. The
values of variables measured by the interval scale were pre-
sented in descriptive values, and the differences were analyzed
through appropriate parametric or nonparametric tests, depend-
ing on the distribution normality (tested by the Kolmogorov–
Smirnov test). All authors had access to the study data and
reviewed and approved the final manuscript.
RESULTS
A total of 804 subjects meeting the inclusion/exclusion
criteria were enrolled in the trial, of which 650 (80.85%) were
included in the final analysis. As shown in Figure 2 and Table 1,
the most common reason for subjects’ exclusion from the final
analysis was failure to adhere to the dosage regimen prescribed
Medicine  Volume 94, Number 17, May 2015by the protocol (N¼ 78) and failure to attend the second and/or
third visit (N¼ 76). Table 1 further shows that at enrolment, the
2 arms were statistically comparable in all observed aspects.
FIGURE 2. Subject distribution by arm.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.The primary objective of the trial was to determine the share of
cured persons in the probiotic treatment arm, in comparison
with the placebo treatment arm. The results in Table 2 show a
significantly larger (P< 0.001) share of cured subjects in the
probiotic arm versus the placebo arm 87.38% (95%
CI¼ 84.33%–90.21%) vs 72.55% (95% CI¼ 69.65%–
75.81%). Additionally, OR, absolute and relative risk
reductions as well as number needed to treat all point strongly
in favor of probiotic arm (Table 2). Owing to a relatively high
patient drop-out rate, a worst/best analysis was performed to
assess the effect of missing data (ie, subjects lost to follow-up as
well as those not complying with the protocol) on the overall
result. In the intention-to-treat analysis (ITT), when all subjects
omitted from the analysis for the above-mentioned reasons
were imputed with the ‘‘worst’’ outcome, that is, they were
considered as not cured at the end of the study period, an OR of
2.08 (95% CI 1.53–2.83) was found. Ratios of cured subjects
were 73.12% and 56.65% for probiotic and placebo arms,
respectively. In the opposite case, that is, when all omitted
subjects were considered as cured (ie, ‘‘best’’ outcome), an OR
of 2.31 (95% CI 1.53–3.51) was found. Ratios of cured subjects
were 87.38% and 72.55% for probiotic and placebo arms,
respectively.
Additionally to primary study outcome (ie, cured/not
cured), presence and intensity for a number of symptoms
(epigastric pain, bloating, flatulence, taste disturbance, loss
of appetite, nausea, vomiting, heartburn, rash, and diarrhea)
were monitored over the study period. The intensity was
measured by the previously described scale consisting of 4
values, where the absence of symptoms was graded as 0, and the
severest symptom intensity was graded as 3. At enrolment,
subjects in both groups had comparable symptoms in terms of
intensity, with P values>0.1 for all symptoms (Mann–Whitney
U test). Same was true for the presence of symptoms (regardless
of their intensity), assessed by x2 test (after Bonferroni correc-
tion for multiple comparisons; Table 1).
In this context, Figure 1 shows presence or absence of
mentioned symptoms at the follow-up visit 15 days postinclu-
sion, in the form of ORs and forest plot. ORs show statistically
significant superiority of probiotic treatment over placebo for 7
of 10 symptoms observed.
DISCUSSIONS AND CONSLUSION
The goal of this trial was to determine objectively the
Probiotics for Helicobacter pylori Eradicationefficacy of probiotics administration as adjuvant therapy in the
standard approach to the treatment of H pylori infection. Owing
to H pylori’s immediate effects of causing gastritis and peptic
www.md-journal.com | 3
TABLE 1. Comparison of Treatment Arms at Baseline
Parameter Probiotic Placebo P
Age, years; mean (SD) 52.3 (13.0) 51.7 (12.8) 0.563
Sex, share of women,
N (%)
179 (53.8) 188 (59.3) 0.154
Education, N (%)
Primary school 4 (1.2) 8 (2.5) 0.218
Secondary school 215 (64.6) 183 (57.7)
College/university 114 (34.2) 126 (39.7)
H pylori infection diagnosis; N (%)
Rapid urease test 44 (13.2) 55 (17.4) 0.314
Urea breath test 134 (40.2) 126 (39.7)
Stool antigen test 155 (46.5) 136 (42.9)
Baseline symptoms of H pylori infection, (present/absent)
Epigastric pain 312/21 291/26 0.351
Bloating 310/23 281/36 0.048
Flatulence 259/74 230/87 0.123
Taste disturbance 133/200 126/191 0.961
Loss of appetite 207/126 172/145 0.042
Nausea 277/56 258/59 0.548
Vomiting 144/189 132/185 0.679
Heartburn 307/26 302/15 0.107
Rash 29/304 27/290 0.931
Diarrhea 116/217 100/217 0.373
Lost to follow-up,
N (%)
34 (8.5) 44 (10.8) 0.150
Noncompliant, N (%) 31 (7.8) 45 (11.1) 0.053
Hauser et alulcer as well as implications of this infection in local tumor-
igenesis and numerous extra intestinal manifestations, its treat-
ment is a frequent and almost routine task of general
practitioners and gastroenterologists. However, standard triple
therapy (STT) approach demonstrates an ever-decreasing per-
centage of cured patients, recently typically <70%.20 This is
mainly because of an increasing resistance to antibiotics
(mainly clarithromycin) and is especially common when anti-
biotics are used in shorter administration regimens, either
intentionally or because of the low compliance.25 Although
the resistance patterns can be avoided by introduction of
different antibiotics, low compliance (mainly because of
adverse events) is a problem that requires a different approach.
In this context, probiotics could represent a valid support to
H pylori¼Helicobacter pylori, SD¼ standard deviation.the STT. Such combination of drugs and probiotics means that
the patient still receives a certain ‘‘gold standard’’ in terms of
therapy, while possibly benefitting from added probiotics.
TABLE 2. Comparison of Groups According to Share of Cured S
Probiotic
Share of cured subjects, N (%) 291/333; 87.38
OR of positive outcome (95% CI) 2.62 (1.71–4.0
ARR in probiotic group (95% CI) 14.8% (8.5%–20
RRR in probiotic group (95% CI) 54.1% (36.8%–69
NNT (95% CI) 7 (5–12)
ARR¼ absolute risk reduction, CI¼ confidence interval, NNT¼ number
Chi-square test.
4 | www.md-journal.comProbiotics address both issues that affect STT efficacy—by
reducing the frequency of side-effects to antibiotic treat-
ment,26,27 they increase patient compliance and by eliminating
the need for additional antibiotics,28 they greatly reduce possib-
ility for antibiotic resistance. Moreover, several species of
probiotics have shown a direct inhibitory activity on H pylori,29
although in clinical trials, the probiotic treatment alone was not
able to completely eradicate the bacterium and thus make the
STT redundant.30
The combination of antibiotic resistance and promising
results of early in-vitro31 studies and animal studies32 have
resulted in a large number of clinical trials mostly in favor of
using probiotics in this indication, although there are diverging
opinions.33,34
A particular and much discussed element of the design of
the present study was selection of disease-specific therapy, that
is, combination of PPIs and antibiotics to be used in each
individual case. According to our protocol, this decision was
solely under discretion of attending physicians. We are fully
aware that most authors choose entirely different method. The
‘‘usual’’ approach involves selecting a limited number of
standard treatment combinations (in this case PPIþ antibiotic),
antibiotic), adding a novel treatment option (in this case a
probiotic) and then controlling for standard treatment combi-
nations in statistical analysis of the effect of a novel treatment
option. For numerous reasons, we see such approach more as a
source of bias and less as a true advantage in study design. First
and most important, it is deeply unrealistic for everyday clinical
or primary care setting. Patients do not receive a limited number
of strictly controlled treatments but rather a wide variety of drug
combinations according to their individual needs. Second, small
number of treatment options can be a benefit and can be
reasonably easily introduced in smaller trials. In larger trials,
such as the one presented here, they pose an organizational and
ethical problems. Third, although it has a clear advantage in
situations wherein treatment introduced is completely novel,
probiotics have already been to some degree proven to be
effective in number of smaller clinical trials. In our opinion,
a large trial can only benefit from the variety of different
treatments. For all the mentioned reasons, we decided to omit
controlling for eradication therapy and embrace a more realistic
scenario of individual treatment approaches. We feel that gains
in understanding of the role of probiotics in such real-life setting
clearly outweigh losing some meticulousness in the statistical
analysis.
With this trial, we attempted to eliminate the shortcomings
observed in a considerable number of previously quoted studies.
Medicine  Volume 94, Number 17, May 2015We are primarily referring to the sample size, which is very
often inadequately small (or the sample calculation procedure is
not even described); hence, the results are impossible to
ubjects, 6 Weeks After Trial Start
Placebo P

% 230/317; 72.55% <0.001
2)
.6%)
.0%)
needed to treat, OR¼ odds ratio, RRR¼ relative risk reduction.
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generalize so as to pertain to the general population. Meta-
analyses somewhat resolve this problem, but can be deficient
with regard to the heterogeneity of subject samples and the
preparations administered. The meta-analysis35 of 14 random-
ized clinical trials (RCTs) with 1671 subjects included trials
with 4 different probiotic strains and 6 additional combinations
of probiotics. Unequal efficacy of these strains and probiotic
combinations is in our opinion a severe drawback of this
analysis. Other meta-analyses upon closer inspection also tend
to display certain population inhomogeneity, such as inclusion
of pediatric population.36 Most of such problems, ranging from
ethnical heterogeneity (important for CYP2C19 polymorph-
isms) to methodological shortcomings reflected in low Jadad
scores of individual clinical trials, have been reviewed in a
recent article by Wang et al.37 Guided by such scrupulous
principles, our intention was to examine a homogenous popu-
lation of a sufficient and statistically validated size, with a
clearly defined hypothesis and applying the identical probiotic
preparation available in most markets.
Our article demonstrates that the share of successfully
cured persons in the group receiving a combination of standard
therapy and probiotic is statistically significantly greater than in
the control group, which received STT only. In the control
group, at 6 weeks post-baseline, the degree of cure was 72.55%,
similar to the one described by other recent studies,27 which
proves the hypothesis on the increased level of resistance to
known antibiotics. The additional use of probiotics results in
absolute risk reduction of negative outcome, that is, persistentH
pylori infection after the end of treatment, of 14.8%.
The second important finding in this trial was also a
considerably more pronounced reduction in disease symptoms
in the probiotic arm, as early as at 2 weeks of treatment, that is,
after the discontinuation of antibiotic administration and before
the beginning of the second part of the treatment in which
therapy is continued only with a PPI over 3 weeks. In the
probiotic arm, ORs were in favor of probiotic treatment for all
symptoms with the exception of rash. For 7 of 10 symptoms,
differences between treatments were statistically significant
(Figure 1).
This study had potential limitations because we included
just patients at primary care setting. Furthermore, patients did
not receive uniform eradication therapy protocol. However, we
aimed to conduct a study that will reflect real-life setting and
whose results can be applied at any general practice office.
Although we stand by our initial decision to compare this novel
treatment approach to ‘‘liberalized’’ triple therapy (as opposed
to a standard and clearly defined number of treatments), follow-
ing is a short discussion of therapies used. According to recent
studies, percentage of clarithromycin resistance in Croatia is as
high as 25.6% in continental part of the country and comparable
22% in coastal regions.38 However, with resistance percentage
rising steeply from only 7% in 1999,39 many primary care
physicians stick by the approach they know and understand—
the standard triple therapy. In Croatia, and consequently in our
study, the most common combinations were omeprazole
(2 20mg) or pantoprazole (2 40mg)þ clarithromycin
(2 500mg)þ amoxicillin (2 x 1000mg) in two thirds of all
study subjects, followed by same combination but with metro-
nidazole (2 400mg) instead of amoxicillin in slightly less
than one quarter of all subjects. A number of other treatments
including lansoprazole as PPI (2 30mg) and azithromycin as
Medicine  Volume 94, Number 17, May 2015antibiotic as well as other combinations were responsible for the
remaining 9% of study treatments. There were no treatment
differences between study arms (P¼ 0,456, x2 test).
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.To put our results in wider perspective and to address the
issue of rationale for conducting the study in the first place,
perhaps the most instructive is a recent study by Molina-Infante
et al.40 After evaluating 9 meta-analyses of usage of probiotics
as adjuvant in H pylori eradication, authors remain sceptic
toward their widespread use for this indication. Although this
is partly our opinion as well, we consider the wide variety of
probiotics used (Lactoferrin, Lactobacillus, alone or combined
with Bifidobacterium, Saccharomyces spp, etc) to be the source
of conflicting results reported in this study and elsewhere.41
One of the rationales for our study was therefore to provide
evidence for using a clearly defined probiotic in a realistic
general care setting. In the future, we hope to conduct a study
that will also clearly address effect of probiotics in different
treatments. However, with levofloxacin still not being regis-
tered for this indication in Croatia and with bismuth not being
on a positive list of approved drugs (ie, patients have to pay full
price for bismuth preparations), the number of realistically
available treatments is smaller compared with other European
countries.42
In light of the results presented, we believe that adding
probiotics to the standard triple therapy for H pylori infection
significantly contributes to treatment efficacy and distinctly
decreases the adverse effects of therapy and the symptoms of
the underlying disease.
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